CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

Rhea-AI Summary

CVRx, a commercial-stage medical device company, announced preliminary unaudited fourth quarter and full year 2024 revenue results, along with its 2025 business outlook.

Fourth quarter revenue is expected to be between $15.2 million and $15.3 million, marking a 35% increase from the previous year's $11.3 million. Full year 2024 revenue is projected to be between $51.1 million and $51.2 million, a 30% increase from 2023's $39.3 million. U.S. revenue for 2024 is expected to be between $47.0 million and $47.1 million, with European revenue at $4.1 million.

For 2025, CVRx forecasts revenue between $63.0 million and $65.0 million, representing a 23% to 27% growth. The company also expects gross margins of 83%-84% and operating expenses between $100.0 million and $104.0 million. First-quarter 2025 revenue is anticipated to be between $14.5 million and $15.0 million.

Notably, the company saw a 41% increase in U.S. heart failure revenue in Q4 2024 and expanded its active implanting centers in the U.S. to 223 by the end of 2024. Additionally, CVRx raised $12.8 million in gross proceeds through its at-the-market offering, increasing its cash and cash equivalents to $105.9 million as of December 31, 2024.

Positive

• Fourth quarter revenue expected to grow by 35%, reaching $15.2 million to $15.3 million.
• Full year 2024 revenue projected to increase by 30%, reaching $51.1 million to $51.2 million.
• U.S. heart failure revenue increased by 41% in Q4 2024.
• Revenue guidance for 2025 set between $63.0 million and $65.0 million, a 23% to 27% growth.
• Gross margins for 2025 expected to be between 83% and 84%.
• Operating expenses for 2025 projected to be between $100.0 million and $104.0 million.
• Cash and cash equivalents stood at $105.9 million as of December 31, 2024.

Negative

• Operating expenses for 2025 projected to be between $100.0 million and $104.0 million, potentially impacting profitability.

Insights

Financial Analyst

The preliminary Q4 and FY2024 results showcase robust revenue growth of 35% and 30% respectively, with Q4 revenue reaching $15.2-15.3 million. The U.S. heart failure segment's impressive 41% growth demonstrates strong market penetration. The company's expansion to 223 active implanting centers and 48 sales territories indicates successful commercial execution.

The 2025 guidance of $63-65 million in revenue suggests continued momentum, though at a slightly moderated growth rate of 23-27%. The projected gross margin of 83-84% is particularly strong for a medical device company, indicating excellent operational efficiency. With $105.9 million in cash and successful ATM offering raising $12.8 million, the company maintains a healthy liquidity position to fund its growth initiatives.

However, the projected operating expenses of $100-104 million for 2025 suggest continued significant investments in commercial expansion, which will impact near-term profitability but potentially drive long-term value creation.

Medical Device Market Analyst

The acceleration in U.S. implanting centers from 208 to 223 in just one quarter represents exceptional market penetration for Barostim therapy. The strategic focus on education, clinical evidence expansion and improved patient access is yielding tangible results in physician adoption rates. The three new sales territories added in Q4 indicate strategic geographic expansion and confidence in market demand.

The successful navigation of reimbursement milestones in 2024 is particularly important for medical device adoption, as it removes a significant barrier to physician utilization. The consistent growth trajectory and expanding footprint suggest Barostim is gaining traction as a standard treatment option in the heart failure space, a market with significant untapped potential.

• Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%
• Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30%
• Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, representing growth of 23% to 27%
  

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited fourth quarter and full year 2024 revenue results and provided its 2025 business outlook.

"We ended 2024 with a strong fourth quarter, highlighted by 41% growth in U.S. heart failure revenue, as we continued to see the benefits of the successful execution of our commercial strategy as well as our focus on increasing education and awareness, expanding our clinical evidence base, and improving patient access,” said Kevin Hykes, President and Chief Executive Officer of CVRx. “Beyond the strength of our revenue performance, we continue to deliver increasing operating leverage as a result of our prudent capital deployment strategy.”

“We are inspired by the exciting prospects of 2025. Having successfully navigated a number of critical reimbursement milestones during 2024, in combination with the positive utilization and adoption momentum we built throughout the year, we believe we are very well positioned to continue to drive strong, sustainable, cost-efficient topline growth in the coming year as Barostim advances toward the standard of care for patients suffering from the debilitating symptoms of heart failure.”

Fourth Quarter 2024

Total revenue for the fourth quarter of 2024 is expected to be in the range of approximately $15.2 million to $15.3 million, representing an increase of approximately 35% over fourth quarter 2023 revenue of $11.3 million. Total revenue generated in the fourth quarter of 2024 is expected to be comprised of approximately $14.2 million to $14.3 million in U.S. revenue and $1.0 million in European revenue.

Full Year 2024

Total revenue for full year 2024 is expected to be in the range of approximately $51.1 million to $51.2 million, representing an increase of approximately 30% over full year 2023 revenue of $39.3 million. Total revenue generated in 2024 is expected to be comprised of approximately $47.0 million to $47.1 million in U.S. revenue and $4.1 million in European revenue.

As of December 31, 2024, the Company had a total of 223 active implanting centers in the U.S., as compared to 208 as of September 30, 2024. The number of sales territories in the U.S. increased by three to a total of 48 during the three months ended December 31, 2024.

As of December 31, 2024, cash and cash equivalents were $105.9 million.

For the three months ended December 31, 2024, the Company issued 869,059 shares of common stock for gross proceeds of $12.8 million under its at-the-market offering.

Business Outlook

For the full year of 2025, the Company expects:

• Total revenue between $63.0 million and $65.0 million;
• Gross margin between 83% and 84%; and
• Operating expenses between $100.0 million and $104.0 million.
  

For the first quarter of 2025, the Company expects to report total revenue between $14.5 million and $15.0 million.

Upcoming Investor Conference Presentation

The Company will be participating in the 43^rd Annual J.P. Morgan Healthcare Conference, including a company presentation on Wednesday, January 15, 2025, at 2:15 pm Pacific Time. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.

About CVRx, Inc.

CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including statements regarding our future financial performance (including our financial guidance regarding full year and first quarter 2025 results), our anticipated growth strategies, anticipated trends in our industry, our business prospects and our opportunities. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “outlook,” “guidance,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history of significant losses, which we expect to continue; our limited history operating as a commercial company and our dependence on a single product, Barostim; our limited commercial sales and experience marketing and selling Barostim; our ability to demonstrate to physicians and patients the merits of our Barostim; any failure by third-party payors to provide adequate coverage and reimbursement for the use of Barostim; our competitors’ success in developing and marketing products that are safer, more effective, less costly, easier to use or otherwise more attractive than Barostim; any failure to receive access to hospitals; our dependence upon third-party manufacturers and suppliers, and in some cases a limited number of suppliers; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide; product liability claims; future lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and ultimately unsuccessful; any failure to retain our key executives or recruit and hire new employees; impacts on adoption and regulatory approvals resulting from additional long-term clinical data about our product; and other important factors that could cause actual results, performance or achievements to differ materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 and in “Part 2, Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as such factors may be updated from time to time in our other filings with the Securities and Exchange Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Preliminary Fourth Quarter/Full Year 2024 Results​

This press release includes estimated financial results for the fourth quarter and full year of 2024, which are preliminary, unaudited and represent the most recent current information available to Company management. The Company’s actual results may differ from these estimated financial results, including due to the completion of its financial closing procedures and final adjustments. The Company expects to issue full financial results for the fourth quarter and full year 2024 in early February.​  

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com

Media Contact:
Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com

FAQ

What are the expected fourth quarter 2024 revenues for CVRX?

CVRx expects fourth quarter 2024 revenues to be between $15.2 million and $15.3 million, representing a 35% increase over the previous year.

What is the full year 2024 revenue growth for CVRX?

The full year 2024 revenue for CVRx is expected to grow by 30%, reaching between $51.1 million and $51.2 million.

What is the revenue guidance for CVRX in 2025?

CVRx expects its 2025 revenue to be between $63.0 million and $65.0 million, representing growth of 23% to 27%.

What are CVRX's expected gross margins for 2025?

CVRx expects its gross margins for 2025 to be between 83% and 84%.

How many active implanting centers did CVRX have in the U.S. at the end of 2024?

As of December 31, 2024, CVRx had 223 active implanting centers in the U.S.

What were CVRX's cash and cash equivalents as of December 31, 2024?

As of December 31, 2024, CVRx had cash and cash equivalents totaling $105.9 million.

How much did CVRX raise through its at-the-market offering in Q4 2024?

CVRx raised $12.8 million in gross proceeds through its at-the-market offering in Q4 2024.